Investigating taste, smell, and sensory functions in patients undergoing stem cell transplantation

Oral, Chemosensory and Trigeminal Functions in Allogeneic Hematopoietic Stem Cell Transplantation - a Prospective Cohort-study

University of Oslo · NCT06003660

This study is trying to see how stem cell transplants affect taste and smell in patients and how these changes might impact their quality of life.

Quick facts

Study typeObservational
Enrollment70 (estimated)
Ages30 Years to 70 Years
SexAll
SponsorUniversity of Oslo (other)
Locations1 site (Oslo, Oslo)
Trial IDNCT06003660 on ClinicalTrials.gov

What this trial studies

This observational cohort study aims to explore the effects of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on taste, smell, and trigeminal functions in patients. The research will assess various sensory functions using standardized tests, including smell and taste assessments, salivary flow measurements, and brain imaging to evaluate changes in relevant cortical regions. Participants will also complete questionnaires to evaluate their quality of life and nutritional status, with comparisons made to healthy controls to identify significant differences. The study seeks to understand the potential sensory dysfunctions that may arise post-transplantation.

Who should consider this trial

Good fit: Ideal candidates are patients receiving myeloablative conditioning for a first-time allo-HSCT diagnosed with leukemia or myelodysplastic syndrome.

Not a fit: Patients with disorders affecting the oral cavity, those on medications impacting sensory functions, or individuals with chronic immune disorders or brain disorders may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved management strategies for sensory dysfunctions in patients undergoing stem cell transplantation.

How similar studies have performed: While this specific approach is novel, similar studies have indicated that sensory dysfunction can occur in patients undergoing stem cell transplantation, suggesting a potential for meaningful insights.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

• patients receiving myeloablative conditioning for a first-time allo-HSCT and diagnosed with either a leukemia or a myelodysplastic syndrome

Exclusion Criteria:

* disorders affecting the oral cavity including poor tooth-status
* those using drugs affecting the gustatory/olfactory functions
* those with brain disorders
* those who have a chronic disorder affecting the immune system, have cancer or who are pregnant.

Where this trial is running

Oslo, Oslo

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Hematopoietic Stem Cell Transplantation

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.